Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The management of patients with overlapping asthma and bronchiectasis requires a tailored approach, starting with a comprehensive assessment of the patient's clinical profile, including the severity of asthma and the extent of bronchiectasis. Inhaled corticosteroids (ICS) are often recommended, but their use should be carefully monitored because of the risk of increased infection. If asthma is well controlled and bronchiectasis remains stable, a gradual reduction in the dose of ICS may be considered. Adjunctive therapies such as macrolides, which have anti-inflammatory and antimicrobial effects, or leukotriene receptor antagonists (LTRAs) may be beneficial. However, LTRAs should be used with caution in patients with bronchiectasis. Long-acting muscarinic antagonists (LAMA), especially in combination with ICS and long-acting beta-agonists (LABA), can improve bronchodilation and reduce inflammation. Although triple therapy (ICS/LABA/LAMA) is promising, its efficacy in bronchiectasis has not yet been confirmed by randomised controlled trials (RCTs). Ongoing monitoring is essential to adjust treatment as the patient's condition evolves. Preventive measures, including vaccination and regular sputum cultures, are important to minimize the risk of infection. Further research and RCTs are needed to better understand the role of dual bronchodilators and triple therapy in the management of overlapping asthma-bronchiectasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rmed.2025.107957 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comorbidities as treatable traits of chronic airway diseases.
Respir Med
August 2025
Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.
Chronic airway diseases, including asthma, chronic obstructive pulmonary disease, and bronchiectasis, are increasingly recognized as heterogeneous conditions influenced not only by airway pathology but also by a wide range of extrapulmonary and behavioral comorbidities. The treatable traits (TT) model, as it has emerged in recent medical literature, offers a precision medicine framework that redefines comorbidities as clinically relevant, identifiable, and modifiable traits. This paradigm shifts the focus from conventional disease labels to a multidimensional approach that considers the individual's unique constellation of pulmonary, extrapulmonary, and psychosocial features.
View Article and Find Full Text PDFSymptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study.
Lancet Respir Med
August 2025
Division of Respiratory Medicine and Gastroenterology, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK. Electronic address:
Background: Previous studies have suggested that daily symptoms are a marker of bronchiectasis disease activity and could therefore identify patients at increased risk of exacerbation. However, international bronchiectasis guidelines recommend long-term macrolide treatment only in patients with three or more exacerbations per year. We aimed to investigate if symptoms independently predict future exacerbations and therefore identify additional responders to long-term macrolide treatment.
View Article and Find Full Text PDFInflammatory and mucociliary dysfunction based endotypes across the spectrum of chronic airway diseases.
Chest
August 2025
Division of Respiratory Medicine and Gastroenterology, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK. Electronic address:
Background: There is substantial overlap between features of COPD, asthma, bronchiectasis(BE) and cystic fibrosis(CF). Each is characterised by inflammation and mucociliary dysfunction.
Research Question: Is there a relationship between inflammation and mucociliary clearance in chronic respiratory conditions and can biology rather than disease labels stratify patients into therapeutically relevant subtypes?
Study Design And Methods: Patients were categorized by primary disease and clinical characteristics, spontaneous sputum was collected, inflammatory markers (neutrophil elastase(NE) and 19 cytokines), sputum properties (DNA content, mucins, rheology, dry weight) and microbiome (long read 16S sequencing) were measured.
From mucus plugging to airway dilatation in chronic airway diseases: A perspective on the contribution of the airway microbiome and inflammation.
Allergol Int
August 2025
Department of Respiratory Medicine & Allergology, Kindai University Faculty of Medicine, Osakasayama, Japan. Electronic address:
Airway mucus plugs are the main pathological and computed tomography (CT) findings that affect clinical outcomes in patients with asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap. Despite the introduction of biologics targeting type 2 inflammation, mucus plug removal remains challenging and understanding its pathogenesis is critical for improved management. In eosinophilic airways, elevated MUC5AC and eosinophil-derived molecules (galectin-10 and extracellular traps) cause highly viscoelastic plugs detectable as high-density regions on ultra-high-resolution CT.
View Article and Find Full Text PDFMapping the Burden and Risk Factors of Allergic Diseases and Asthma Among Aboriginal and Torres Strait Islander People: A Scoping Review.
Clin Exp Allergy
August 2025
Child Health Research Centre, The University of Queensland, South Brisbane, Queensland, Australia.
Allergic diseases and asthma are significant public health concerns in Australia and globally. However, comprehensive data on the burden among Aboriginal and Torres Strait Islander people are scarce. This scoping review aimed to systematically map existing evidence on the burden and risk factors of allergic diseases and asthma among Aboriginal and Torres Strait Islander people.
View Article and Find Full Text PDF